

1           **SYMPATHETIC PREDOMINANCE IS ASSOCIATED WITH IMPAIRED**  
2           **ENDOTHELIAL PROGENITOR CELLS AND TUNNELING NANOTUBES IN**  
3           **CONTROLLED-HYPERTENSIVE PATIENTS**

4           Elena M.V. de Cavanagh<sup>1,2</sup>; Sergio A. González<sup>1,2</sup>; Felipe Inserra<sup>1</sup>; Pedro Forcada<sup>1,2</sup>;  
5           Carlos Castellaro<sup>1,2</sup>; Jorge Chiabaut-Svane<sup>1,2</sup>; Sebastián Obregón<sup>1,2</sup>; María Jesús  
6           Casarini<sup>2</sup>; Pablo Kempny<sup>2</sup>; Carol Kotliar<sup>1,2</sup>

7  
8

9           **Contributions of Authors**

10          Design and conceptualization of the study: EMVC, SG, FI, CK  
11          Literature Search: EMVC, SG, JCS  
12          Data acquisition: EMVC, SG, MJC  
13          Provided and cared for study patients: SG, MJC, PF, JCS, SO, PK, JCS  
14          Analysis of the data: EMVC, SG, MJC, SO  
15          Statistical analysis: EMVC, SG, CC  
16          Interpretation of the data: EMVC, SG, FI, CK  
17          Drafting the manuscript: EMVC, SG, JSV  
18          Revising the manuscript: EMVC, SG, FI, PF, CC, SO, JCS, MJC, PK, CK  
19          Overall management: EMVC, PK  
20          Laboratory Supervision: PF, CC, SO, JCS  
21          Quality assurance and Control: CC, PF, PK

22  
23

24          <sup>1</sup>School of Biomedical Sciences, Austral University; <sup>2</sup> Arterial Hypertension Center,  
25          Cardiology Department, Austral University Hospital, Av. JD Perón 1500 (B1664INZ),  
26          Derqui, Pilar, Prov. Buenos Aires, Argentina

27  
28

29          **Running Head:** Endothelial progenitors, autonomic activity and hypertension

30  
31  
32

33          **Corresponding Author:**

34          Elena M. V. de Cavanagh  
35          School of Biomedical Sciences  
36          Arterial Hypertension Center, Austral University Hospital, 3<sup>rd</sup> floor  
37          Av. Juan Domingo Perón 1500 -ex ruta 234 - (B1664INZ) Pilar  
38          Phone: +54 2304 482210  
39          Fax No.: +54 2304 482832  
40          ecavanag@cas.austral.edu.ar  
41          elenacavanagh@yahoo.com.ar (this address is used more frequently)

42 **ABSTRACT**

43 **Objective.** Early-endothelial progenitor cells (early-EPC) and late-EPC are involved in  
44 endothelial repair, and can rescue damaged endothelial cells by transferring organelles  
45 through tunneling-nanotubes (TNT). In rodents, EPC-mobilization from the bone  
46 marrow depends on sympathetic nervous system activity. Indirect evidence suggests a  
47 relation between autonomic derangements and human EPC-mobilization. We aimed at  
48 testing whether hypertension-related autonomic imbalances are associated with EPC  
49 impairment. **Results.** Thirty controlled-essential hypertensive patients  
50 [SBP/DBP=130(120-137)/85(61-88) mmHg; 81.8% male], and twenty-healthy  
51 normotensives [(114(107-119)/75(64-79) mmHg; 80% male] were studied.  
52 Mononuclear cells were cultured on fibronectin- and collagen-coated dishes for early-  
53 EPC and late-EPC, respectively. Low-(LF) and high-frequency (HF) components of  
54 short-term heart rate variability were analyzed during a 5-min rest, an  
55 expiration/inspiration maneuver, and a Stroop color-word-test. Modulations of cardiac  
56 sympathetic and parasympathetic activities were evaluated by LF/HF (%) and HF-  
57 power ( $\text{ms}^2$ ), respectively. In controlled-hypertensive patients, the numbers of early-  
58 EPC, early-EPC that emitted TNT, late-EPC and late-EPC that emitted TNT were 41%,  
59 77%, 50% and 88% lower than in normotensives ( $p < 0.008$ ). In controlled-hypertensive  
60 patients, late-EPC number was positively associated with cardiac parasympathetic  
61 reserve during the expiration/inspiration maneuver ( $\text{Rho} = 0.45$ ,  $p = 0.031$ ) and early-EPC  
62 with brachial flow-mediated dilation ( $\text{Rho} = 0.655$ ;  $p = 0.049$ ); also, late-TNT number was  
63 inversely related to cardiac sympathetic response during the stress-test ( $\text{Rho} = -0.426$ ,  
64  $p = 0.045$ ). EPC exposure to epinephrine or norepinephrine showed negative dose-  
65 response relationships on cell adhesion to fibronectin and collagen; both  
66 catecholamines stimulated early-EPC growth, but epinephrine inhibited late-EPC  
67 growth. **Conclusions.** In controlled-hypertensive patients, sympathetic  
68 overactivity/parasympathetic underactivity were negatively associated with EPC,

69 suggesting that reducing sympathetic/increasing parasympathetic activation might  
70 favor endothelial repair.

71

72 **Key Words:** endothelial regeneration, autonomic balance, parasympathetic

73

74

75

## 76 **Introduction**

77 Current evidence supports the concept that circulating bone marrow-derived  
78 endothelial progenitor cells (EPCs) contribute to the repair and regeneration of the  
79 injured endothelium(15). Tissue ischemia and/or endothelial damage promote EPC  
80 mobilization from the bone marrow, and EPC recruitment and incorporation at sites of  
81 vascular damage (15). Two distinct types of EPC have been identified by *in vitro* cell  
82 culture of the blood mononuclear cell fraction, i.e., early-EPC and late-EPC, the latter  
83 also known as outgrowth endothelial cells. Early-EPC –representing alternative  
84 activated M2 macrophages- promote vascular repair through the paracrine release of  
85 cytokines, and late-EPC by differentiating into endothelial cells and incorporating into  
86 blood vessels (20, 26). In addition, EPC can rescue damaged endothelial cells by  
87 transferring mitochondria and lysosomes through the recently discovered cell-to-cell  
88 communication channels referred to as tunneling nanotubes (TNT) (34, 35).

89 Studies in rodents showed that the sympathetic nervous system plays an essential role  
90 in EPC mobilization from the bone marrow (22), and that catecholamines are involved  
91 in the modulation of post-ischemic revascularization (31), suggesting that autonomic  
92 dysregulation can impair vascular endothelial repair. In humans, the relation between  
93 sympathetic activation and EPC egress from the bone marrow was indirectly suggested  
94 by reports showing a negative relation between the number of circulating EPC and both  
95 psychosocial stressors (13) and depression scores (8), which are known to be  
96 associated with autonomic derangements. In this context, it is noteworthy that *in vivo*  
97 endothelial repair capacity is reduced in prehypertension and hypertension patients  
98 (16), and that sympathetic overactivation has been calculated to be present in  
99 approximately 50% of essential hypertension patients (10, 30).

100 Considering all the above, we postulated that autonomic imbalances characterized by  
101 sympathetic overactivation and/or parasympathetic inhibition would be associated to  
102 impaired endothelial repair capacity in treated hypertensive patients. To test this

103 notion, in this study we assessed the relations between the number and function of  
104 EPCs and autonomic status in patients under treatment for hypertension that had  
105 achieved goal blood pressure, and also investigated *ex vivo* EPC responses to added  
106 epinephrine and norepinephrine.

107

## 108 **Materials and Methods**

### 109 **Patients**

110 The study adhered to the principles outlined in the Declaration of Helsinki and was  
111 approved by the School of Biomedical Sciences-Austral University Ethics Committee.  
112 Written informed consent was obtained from all subjects. A total of 90 individuals that  
113 consulted consecutively at the Center of Hypertension of the Austral University Hospital  
114 were screened for the following exclusion criteria: previous cardiovascular events,  
115 diabetes, smoking history, and cancer. Thirty treated essential hypertensive patients  
116 (Hypertensive group) that had achieved goal blood pressure were included. Patients  
117 were asked to interrupt their antihypertensive medications for 24 h in advance of the  
118 day when they underwent anthropometric, metabolic (fasting glycemia and lipid profile),  
119 autonomic and flow-mediated dilation evaluations. Twenty healthy normotensive  
120 volunteers (Normotensive group), that were not receiving any medication, were studied  
121 to obtain reference values for EPC and TNT. Office blood pressure was measured with  
122 a calibrated and validated semiautomatic oscillometric device (Omron HEM-781CPINT,  
123 Omron Healthcare, Inc., Lakeside Drive Bannockburn, IL ) according to JNC7 (9), with  
124 an appropriate cuff size and by averaging the second and third readings after the  
125 patients had been seated for 5 min.

### 126 **Assessment of autonomic function.**

127 In Hypertensive patients, heart rate variability (HRV) was measured in the morning  
128 after 40 minutes of supine rest in a quiet room, at 22 °C. Frequency domain analysis of  
129 short-term HRV was performed by using an autoregressive model (Kubios software,  
130 Finland) in 3 settings: basal (during a 5-min supine rest), during a deep breathing

131 maneuver (E/I maneuver, with 6 metronomic breaths/minute), and while performing a  
132 mental stress test (Stroop color-word test). Beat-to-beat R-R intervals (RRI; i.e. HRV)  
133 and systolic blood pressure (SBP) were continuously monitored throughout these  
134 maneuvers (1)(29).

135 Spectral analysis of HRV data yielded the low (0.05-0.15 Hz, LF) and high (>0.15 Hz,  
136 HF) frequency components of total power. For the assessment of autonomic balance,  
137 the cardiac parasympathetic reserve was evaluated by analyzing HF ( $\text{ms}^2$ ) during both  
138 the 5-min rest period and the E/I maneuver, whereas the cardiac sympathetic response  
139 was assessed by analyzing the LF/HF ratio (%) during the 5-min rest and the mental  
140 stress test.

#### 141 **EPC culture and characterization**

142 A 40-mL sample of venous blood was used for the isolation of EPC by density gradient  
143 centrifugation (Histopaque 1077, Cat. No. H8889, Sigma-Aldrich, St. Louis, MO).

144 Samples were processed within 2 h after collection. The mononuclear peripheral blood  
145 cells were washed once with phosphate buffered saline and twice in growth medium  
146 (BioCoat Endothelial Cell Culture Environment, Cat. No. 355054, Becton Dickinson,  
147 Bedford, MA) supplemented with 20 % fetal-calf serum, penicillin (100 U/mL),  
148 streptomycin (100  $\mu\text{g}/\text{mL}$ ) and amphotericin B (0.25  $\mu\text{g}/\text{mL}$ ). The isolated cells were  
149 resuspended in growth medium and plated onto human fibronectin-coated (Cat. No.  
150 354559) or rat collagen-coated (Cat. No. 354557) 6 well dishes (BioCoat cellware,  
151 Becton Dickinson, Bedford, MA) for early-EPC ( $5 \times 10^6$  cells/well) and late-EPC ( $2 \times 10^7$   
152 cells/well), respectively. After 48 h, the non-adherent cells were discarded, and the  
153 adherent cells were cultured during 9 days or 21 days for early-EPC and late-EPC,  
154 respectively (27). Growth medium was changed every other day, and digital  
155 photographs were obtained. To confirm the endothelial phenotype, at the end of the  
156 growth curve, cultured cells were characterized by exposure to Dil-acetylated low-  
157 density lipoproteins (Cat. No. L3484, Invitrogen, Carlsbad, CA), FITC-conjugated lectin  
158 from *Ulex europaeus* (Cat. No. L9006, Sigma-Aldrich, St. Louis, MO), and monoclonal

159 antihuman PE-conjugated CD45 (Cat. No. P7687, Sigma-Aldrich). CD14 and vascular  
160 endothelial growth factor receptor-2 (VEGFR-2) were revealed by indirect fluorescence  
161 immunohistochemistry, by using monoclonal anti-human CD14 (Cat. No. C7673,  
162 Sigma-Aldrich) and VEGFR-2 (Cat. No. V3003, Sigma-Aldrich) antibodies, followed by  
163 FITC-conjugated anti-Mouse IgG (Cat. No. F5687, Sigma-Aldrich). TNT were identified  
164 by microscopy and fluorescent phalloidin staining (Alexa Fluor® 594 phalloidin, Cat.  
165 No. A12379, Molecular Probes, Life Technologies, Carlsbad, CA) on days 9 and 21 for  
166 early-EPC and late-EPC, respectively. Digital images and Cell C software (Tampere  
167 University of Technology, Finland) were used to count the cells in 6 randomly selected  
168 microscopic fields/well, by one operator that was blinded as to the corresponding  
169 subject's group. TNT were quantified manually on digital images by one observer that  
170 was masked to the subject's group. For EPC and TNT counting, intraobserver  
171 variabilities -assessed by calculating the coefficient of variation [ $CV(\%) = \text{Mean of SD} \times$   
172  $100 / \text{Data Mean}$ ]- were 5.0 % and 5.3 %, respectively. The inter-assay CV% were 7.5  
173 % and 7.1 % for EPC and TNT counting, respectively.

#### 174 **Effects of epinephrine and norepinephrine on cultured EPC**

175 Early- and late-EPC were cultured in the presence of epinephrine hydrochloride (Cat.  
176 No. E4642, Sigma-Aldrich) or norepinephrine bitartrate (Cat. No. A9512, Sigma-  
177 Aldrich) that were dissolved in phosphate buffered saline (PBS) and added to the  
178 culture medium at the final epinephrine concentrations reported for human plasma (11)  
179 at standing, during exercise and in response to other types of stress (25, 100 and 400  
180 ng/L, respectively; n= 6 independent assays each) and at plasma norepinephrine levels  
181 reported at standing and during exercise (100 and 200 ng/L, respectively) (17). Control  
182 cells were added with PBS. To test the effects of these catecholamines on EPC  
183 adhesion to fibronectin and collagen, epinephrine or norepinephrine were added to the  
184 mononuclear cell culture medium at the time of seeding onto the respective culture  
185 dishes, and adherent EPC were counted 48 h later; whereas to test their effects on

186 EPC growth, mononuclear cells were seeded onto fibronectin or collagen in the  
187 absence of epinephrine or norepinephrine, and 48 h later -after having discarded non-  
188 adherent cells- the catecholamines were added to adherent EPC. The catecholamine  
189 supplemented media were replaced every 48 h, and early- and late-EPC were counted  
190 on days 9 or 21, respectively, as was described in "EPC culture and characterization".

191

### 192 **Brachial artery flow-dependent endothelium-mediated dilation**

193 To evaluate endothelial function status in treated hypertensive patients, brachial artery  
194 flow-dependent endothelium-mediated dilation was measured in the morning under  
195 fasting conditions, with patients supine in a quiet room kept at 22°C using a high  
196 resolution device (Esaote Caris 7230, Genova, Italy). The International Brachial Arterial  
197 Reactivity Task Force guidelines were followed (7). In brief, brachial artery diameter  
198 measurements were obtained with a 10-MHz transducer positioned perpendicular to  
199 the vessel in the upper arm by using a stereotactic clamp to ensure that the  
200 measurements were made in the same arterial segment, and to avoid transducer  
201 displacement. Ultrasonic gel was used as the transmitting medium. Brachial artery  
202 blood flow velocity was obtained continuously by pulsed Doppler signal, in the arm  
203 opposite to that used for blood extraction. After positioning a blood pressure cuff in the  
204 upper arm, baseline vessel diameter and blood flow were acquired. The cuff was then  
205 inflated to  $\geq 10$  mmHg above systolic blood pressure, to occlude arterial flow for 3  
206 minutes. Continuous recordings of the longitudinal image of the artery were obtained  
207 starting 30 s before and up to 2 minutes after cuff deflation. To assess hyperemic flow,  
208 the Doppler signal was registered immediately after cuff release for a maximum of 15  
209 seconds. The information obtained was processed with a Hemodyn 4M instrument. The  
210 flow-mediated dilator response, expressed as a percentage of the baseline brachial  
211 artery diameter, was used as an estimation of endothelium-dependent vasodilation.  
212 This method is routinely used in our laboratory.

213

214

**215 Statistical analysis**

216 Since the data were not normally distributed, differences between the Hypertensive  
217 and Normotensive groups in median values of EPC and TNT and of anthropometric  
218 variables were tested by the nonparametric Mann–Whitney *U* test.

219 Correlations between EPC parameters and autonomic evaluation parameters were  
220 assessed both by Spearman rank order correlation test (for not normally distributed  
221 data) and by simple linear regression after natural logarithmic transformation of the  
222 variables. Multivariate linear regression analysis with either EPC or TNT as predicted  
223 variables and autonomic evaluation, anthropometric/metabolic parameters and blood  
224 pressure as predictor factors was assessed according to the forward-stepwise method.  
225 Those parameters appearing clearly uncorrelated to EPC or TNT numbers by the  
226 Spearman test and simple linear regression were excluded from the multivariate  
227 analysis.

228

**229 RESULTS***230 Subjects' characteristics*

231 The characteristics of the study subjects are shown in Table 1. The Hypertensive and  
232 Normotensive groups showed no differences in age and gender distribution, BMI, LDL-  
233 and HDL-cholesterol levels, and glycemia. In the Normotensive group systolic and  
234 diastolic blood pressures were significantly lower than in the Hypertensive group. Also,  
235 in the Hypertensive group plasma triglycerides and total cholesterol were higher than in  
236 the Normotensive group, although the differences reached statistical significance only  
237 for triglycerides.

238

*239 Cultured early-EPC, late-EPC, and TNT identification*

240 Early-EPCs and late-EPCs were obtained from human peripheral blood according to  
241 established protocols. After *ex-vivo* culture, each type of EPC homogeneously  
242 exhibited their distinctive morphology, i.e., early-EPC were spindle-shaped cells and

243 late-EPC exhibited a cobblestone appearance. After immunophenotyping, early-EPC  
244 were identified as CD14+, CD45+, AcLDL+, UEA1+, VEGFR-2+ cells on day 9 of  
245 culture, and late-EPC as CD14-, CD45-, AcLDL+, UEA1+, VEGFR-2+ cells (day21)  
246 (Figure 1A). Therefore, as expected, early-EPC –but not late-EPC- expressed the  
247 haematopoietic markers CD14 and CD45, indicating that late-EPC are committed to  
248 the endothelial lineage.

249 To ascertain that CD14 and CD45 positive cells were not a mixture of live and dead  
250 cells, we first stained early-EPC with Dil-acetylated LDL that is taken-up through  
251 receptor-mediated endocytosis and functions as a live cell marker. Since we could not  
252 co-stain cells with CD45 fluorescent and Dil-acetylated LDL antibodies, because they  
253 both emitted light in the red region, we used an indirect approach consisting of two  
254 steps: 1) we co-stained cells with Dil-acetylated LDL and a green fluorescence CD14  
255 antibody, and found that all CD14+ cells were live cells, since they were also Dil-  
256 acetylated LDL+ cells (Figure 1B), and 2) we co-stained cells with CD45 with CD14  
257 antibodies (red and green fluorescence, respectively), and showed that all CD45+ cells  
258 were also CD14+ cells (Figure 1B). Figure 1B also shows that early EPC were positive  
259 for both VEGFR-2 and CD45.

260 Tunneling nanotubes were characterized as thin, straight, actin-rich cytoplasmic  
261 projections, with a length equivalent to several cell diameters, and crossing from one  
262 cell to another (Figure 2).

263

264 *Ex vivo cultured early-EPC, late-EPC and TNT are reduced in controlled essential*  
265 *hypertensive patients*

266 Table 2A shows the quantification of EPC and TNT (i.e., tunneling nanotubes projected  
267 by EPC). TNT counting refers to the total number of EPC emitting tunneling nanotubes  
268 per microscopic field. For early-EPC and late-EPC, TNT started to be evident on days  
269 5 and 10 of culture, respectively. In the Hypertensive group, early-EPC and early-TNT,

270 late-EPC and late-TNT were significantly less abundant than in the Normotensive  
271 group (43 %, 78 %, 51 % and 89 %, respectively).

272 The percentage of early-EPC and late-EPC that emitted TNT was significantly lower in  
273 Hypertensive patients than in Normotensive individuals (Table 2B).

274  
275 *Relation between autonomic status and EPC numbers in controlled essential*  
276 *hypertensive patients*

277 Table 3A shows cardiac parasympathetic reserve and sympathetic response as  
278 evaluated by analyzing the HF and LF/HF ratio components of heart rate variability in  
279 the Hypertensive group, during a 5-min rest, the E/I maneuver, and the mental stress  
280 test.

281 Considering that the data were not normally distributed, the Spearman correlation  
282 coefficient was used to assess the strength of the relation between variables. However,  
283 given that the robustness of Spearman correlation is lower than that of Pearson  
284 correlation coefficient, we also used the latter method after normalization by natural  
285 logarithmic transformation of the data.

286 In the Hypertensive group, late-EPC number was positively related to the cardiac  
287 parasympathetic reserve during the E/I maneuver, both when assessed by statistical  
288 non-parametric analysis (Table 3B) and after natural logarithmic transformation and  
289 linear regression analysis (Figure 3).

290 In contrast, in the Hypertensive group late-TNT numbers were negatively associated  
291 with cardiac sympathetic response during the mental stress test (Table 3B). During the  
292 rest period, no relations were found between either early-EPC, early-TNT, late-EPC or  
293 late-TNT and cardiac parasympathetic reserve or sympathetic response.

294 To establish whether risk factors or hypertensive patients' characteristics other than  
295 cardiac parasympathetic reserve and sympathetic response might have partly  
296 explained the reduced late-EPC and late-TNT counts, a multiple linear regression  
297 analysis was performed. No relations were found between any of early-EPC, late-EPC,

298 early-TNT, late-TNT and either BMI, glycemia, TG, Total/HDL/LDL Cholesterol, blood  
299 pressure (SBP/DBP) or age. Therefore, for multivariate linear regression analysis with  
300 either late-EPC or late-TNT numbers as predicted variables, only autonomic evaluation  
301 parameters (HF during the E/I maneuver and LF/HF ratio during the stress test,  
302 respectively) could be used as predictor factors.

303

#### 304 *Effects of epinephrine and norepinephrine on cultured EPC*

305 Since correlation analysis is not sufficient proof of causation, early- and late-EPC were  
306 cultured in the presence of epinephrine or norepinephrine to test whether plasma  
307 catecholamine levels might contribute to the negative association observed in  
308 hypertensive patients between sympathetic overactivity/parasympathetic underactivity  
309 and EPC and TNT numbers. Exposure of EPC to epinephrine showed a negative dose-  
310 response relationship on cell adhesion to fibronectin; thus, at 25 ng epinephrine/L the  
311 number of adherent cells 48 h after seeding was 13 % lower (not significant) than early-  
312 EPC treated with PBS, but at 100 and 400 ng epinephrine/L cell adhesion was  
313 progressively and significantly reduced by 34 % and 63 %, respectively (Figure 4-A1).  
314 A negative dose-response behavior was also observed when the cells were exposed to  
315 norepinephrine at 100 ng/L and 400 ng/L, which decreased EPC adhesion to  
316 fibronectin by 16 % (not significant) and 50 %, respectively, relative to PBS-treated  
317 cells (Figure 4-A1). However, when seeded over collagen, cell incubation with  
318 epinephrine at 100 ng/L and 400 ng/L or norepinephrine at 200 ng/L slightly but  
319 significantly reduced EPC adhesion (by 3.7 %, 7.7 % and 3.6 %, respectively)  
320 compared with cells incubated in the presence of PBS (Figure 4-A2).

321 In contrast, exposure to epinephrine showed a positive dose-response relationship on  
322 early-EPC growth, i.e. early-EPC count on day 9 of culture was 17 % and 39 % higher  
323 in cells incubated with epinephrine at 100 ng/L and 400 ng/L, respectively, relative to  
324 PBS-treated cells, whereas 25 ng epinephrine/L had no effect. Incubation of early EPC  
325 with norepinephrine at 100 ng/L and 200 ng/L stimulated cell growth by 43 % and 41

326 %, respectively, relative to incubation without norepinephrine (Figure 4-B1). When  
327 cultured over collagen, incubation with norepinephrine had no effect on late-EPC  
328 growth, and only 400 ng epinephrine/L reduced cell growth by 20 % versus PBS-  
329 treated cells (Figure 4-B2).

330

331 *The amount of cultured early-EPCs is positively correlated with flow-dependent,*  
332 *endothelium-mediated dilation*

333 In controlled hypertensive patients, the median value for brachial artery flow-  
334 dependent, endothelium-mediated dilation (FMD) was 4.88 %, with minimum and  
335 maximum values of 0 % and 19.3 %, respectively.

336 *Ex vivo* cultured early-EPC counts were positively correlated with brachial artery FMD  
337 [Spearman rho = 0.655; p = 0.049; and linear regression analysis (Figure 5)].

338 No relation was found between the arterial blood flow response [median (max-min  
339 values) = 139 (68-181) ml/min] to reactive hyperemia and FMD (Spearman rho =  
340 0.036; p= 0.8342), indicating that although increases in blood flow-associated shear  
341 stress are known to trigger the vasodilatory response, other factors exerted a  
342 predominant influence on FMD modulation.

343

## 344 **DISCUSSION**

345 The present work shows that in the treated essential hypertensive patients studied,  
346 although the blood pressure achieved was within the range recommended by the JNC7  
347 guidelines, a) the number and function of *ex vivo* cultured early- and late-EPC are  
348 reduced when compared with normotensive subjects, b) an autonomic profile  
349 characterized by sympathetic overactivity/parasympathetic underactivity is negatively  
350 associated with EPC and TNT numbers, and c) epinephrine and norepinephrine  
351 negatively affect early- and late-EPC adhesion and to a lesser extent stimulate *ex-vivo*  
352 early-EPC growth, whereas epinephrine reduces late-EPC growth, d) a positive  
353 correlation exists between cultured early-EPC counts and the extent of brachial flow

354 mediated dilation, indirectly suggesting that EPC alterations are associated with, and  
355 can have detrimental effects on, vascular function.

356 Given that no relations were found between any of early-EPC, late-EPC, early-TNT,  
357 late-TNT and plasma triglycerides, total cholesterol, or systolic/diastolic blood  
358 pressures it follows that the lower number and function of *ex vivo* cultured early- and  
359 late-EPC observed in hypertensive patients relative to normotensive subjects was not  
360 dependent on the differences observed in these particular parameters between both  
361 groups.

362 To the best of our knowledge, this is the first report to show that both cultured late-EPC  
363 counts and the number of early- and late-EPC that emit TNT are lower in controlled  
364 hypertensive patients relative to normotensive subjects. The relevance of TNT  
365 formation by EPC is evidenced by puzzling data showing that the marked improvement  
366 of vascular repair by transplantation of EPC is accompanied by scarce EPC  
367 engraftment at injury sites (37). This apparent contradiction can be explained, at least  
368 partly, by recent evidence showing that *in vitro* and *in vivo* the formation of TNT by  
369 EPC is responsible for the rescue of prematurely senescent endothelial cells; this  
370 involves TNT-mediated transfer of lysosomes from EPC to endothelial cells, which  
371 reconstitutes the lysosomal pool of stressed endothelia and improves their viability and  
372 function (34). In this context, a previous report showed that essential hypertensive  
373 patients have an increased proportion of senescent *ex-vivo* cultured EPC relative to  
374 normotensive individuals, and that the extent of hypertension-related organ damage  
375 was positively related to EPC senescence (21).

376 The number of TNT reported here represents the basal level of TNT expression by  
377 cells under normal tissue culture conditions. The lower early- and late-TNT numbers  
378 observed in cultured cells from controlled hypertensive patients relative to  
379 normotensive subjects cannot be extrapolated the *in vivo* situation; however,  
380 considering that TNT contribute to cell survival, the present *ex vivo* finding is consistent  
381 with the well-documented reduction of *in vivo* endothelial repair capacity that occurs in

382 prehypertension and hypertension patients. At present, the signals that guide tunneling  
383 nanotube formation are not completely understood. It should be mentioned, that apart  
384 from EPC, TNT were described in other cell types. Also, TNT can facilitate not only the  
385 transfer of lysosomes but also that of mitochondria, plasma membrane components,  
386 vesicles, Ca<sup>2+</sup>, pathogens and electrical signals. This novel type of intercellular  
387 communication participates in such vital processes as tissue regeneration, signal  
388 transmission, development, and immunity (2) . According to our present results, it can  
389 be suggested that in treated hypertensive patients the alterations in TNT formation may  
390 negatively affect EPC function despite having achieved adequate blood pressure  
391 values through pharmacological treatment.

392 Here we observed that in treated hypertensive patients the cardiac parasympathetic  
393 reserve was positively related to *ex vivo* cultured late-EPC levels, whereas cardiac  
394 sympathetic response was negatively associated with TNT numbers in late-EPC  
395 cultures. These results suggest that normalization of the sympathetic/parasympathetic  
396 balance may increase EPC levels and improve their function, thereby enhancing the  
397 capacity for endothelial repair in essential hypertensive patients. The latter concept is  
398 supported by both the observed negative dose-response relationship on *ex-vivo* EPC  
399 adhesion to fibronectin and collagen, as well as epinephrine's inhibitory effect on late-  
400 EPC growth. Although both epinephrine and norepinephrine stimulated early-EPC  
401 growth, the magnitude of the effect was smaller than the detrimental influence on EPC  
402 adhesion. The observed stimulation of early-EPC growth by catecholamines is a  
403 puzzling finding for which we can only provide a speculative reasoning. Since early-  
404 EPC represent alternative activated M2 macrophages, we have drawn a potential  
405 interpretation from known macrophage responses to catecholamines. The sympathetic  
406 nervous system has a dual role –i.e., either anti-inflammatory or pro-inflammatory- on  
407 local inflammatory responses mediated by the actions of norepinephrine and  
408 epinephrine on immune cell adrenoreceptors (12). In the case of macrophages, the  
409 effects of catecholamines on cell functions seem to be complex and subject to

410 inconsistencies. It has been proposed that the discordance between stimulatory and  
411 inhibitory actions of catecholamines is dependent upon the activation state of  
412 macrophage populations and the associated changes in the expression levels of  
413 different adrenoceptor types. In this context, to clarify the significance of our  
414 unexpected observation that catecholamines stimulated the *in vitro* growth of early-  
415 EPC, other studies are needed to assess the expression of adrenoceptors under the  
416 present experimental conditions. Finally, considering that early-EPC are supportive  
417 cells that by releasing cytokines can modulate the vasculogenic activity of late EPC, it  
418 is feasible that in the setting of autonomic dysregulation the stimulation of early-EPC  
419 growth by epinephrine and norepinephrine might represent a counterbalancing  
420 mechanism aimed at buffering the negative effects of both catecholamines on early-  
421 and late-EPC and minimizing any deleterious consequences on vascular maintenance.  
422 In recent years, the sympathetic nervous system was identified as a decisive  
423 determinant in progenitor cell mobilization from the bone marrow (22). In relation to  
424 this, EPC were shown to express functional  $\beta$ 2-adrenergic receptors which upon  
425 stimulation induce EPC migration, proliferation and differentiation, resulting in improved  
426 neoangiogenesis in experimental hindlimb ischemia (14). Interestingly, in chronic  
427 obstructive pulmonary disease patients  $\beta$ 2-adrenergic receptor expression in early-  
428 EPCs was higher than in healthy controls, and treatment of EPC with a  $\beta$ 2-adrenergic  
429 receptor antagonist (ICI 118551) increased EPC migration and proliferation when  
430 compared to treatment with an agonist, norepinephrine (24). Concerning the link  
431 between the parasympathetic nervous system and EPC, approximately a decade ago a  
432 previously unknown cholinergic angiogenic pathway mediated by nicotinic acetylcholine  
433 receptors (nAChRs) on endothelial cells, was described (19). Later, nAChR activation  
434 by both local and systemic administration of nicotine was shown to increase the  
435 mobilization and/or recruitment of mouse EPC to the site of angiogenesis in ischemic  
436 tissues (18); also, nAChRs were identified on fibronectin-cultured human EPCs, and  
437 nicotine -via nAChRs - was found to improve human EPCs functional activity (36). The

438 archetypal endogenous nAChR agonist is acetylcholine (ACh). The broad hydrolyzing  
439 activity of acetylcholinesterase and butyrylcholinesterases in neuronal and non-  
440 neuronal tissues, including vascular cells (23) reduces ACh actions to local paracrine  
441 or autocrine effects. Of note, choline -that is released from acetylcholine by  
442 acetylcholinesterase- can activate at least one of the nAChRs subtypes, i.e. the  
443 homomeric  $\alpha 7$  nAChRs (4) ; therefore, after ACh hydrolysis a chance for ACh signaling  
444 still remains. Considering the above evidence, it is feasible that ACh (or other longer-  
445 lasting nAChR agonists) released from nerve endings may be involved in vascular  
446 growth or maintenance. Circumstantial evidence supports the latter concept; thus, as  
447 pointed out by Cooke et al. (6), the reduced foot-healing capacity associated to  
448 diabetes is preceded by a severe neuropathy, raising the question of whether in  
449 diabetic patients the loss of nerve-produced trophic agents, including ACh, might  
450 participate in the deterioration of angiogenesis. Finally, although parasympathetic  
451 innervation to the bone marrow had not been previously reported, parasympathetic  
452 activity was recently detected in the skeletal bone marrow, where ACh functioned to  
453 decrease bone resorption (5) .

454 Our observations that peripheral blood mononuclear cells from controlled hypertensive  
455 patients gave rise to a lower number of cultured early-EPC than those from  
456 normotensive subjects, and that early-EPC numbers are positively related to flow  
457 mediated dilation, are in line with previous findings by others (16).

458 Although the antihypertensive treatments were discontinued for 24 h previous to blood  
459 sampling, some of the drugs used by the study population (RAAS blockers,  
460 dihydropyridine  $Ca^{2+}$  antagonists) may have influenced autonomic balances. However,  
461 it should be considered that the cardiac sympathetic response during the mental stress  
462 test was negatively associated with late-TNT numbers, but both kinds of compounds  
463 have been described to lower sympathetic activity. Therefore, if an autonomic effect did  
464 occur, a confounding influence by RAAS blockers or dihydropyridine  $Ca^{2+}$  antagonists  
465 would have weakened the above association, instead of strengthening it. Also,

466 although statins have been shown to increase the level of circulating EPC (32), no  
467 differences were observed here between hypertensive patients receiving and not  
468 receiving statins.

469 Injured tissues release a variety of mediators that attract EPC to the site and ensure  
470 their engraftment (25, 28). In this setting, in coronary artery disease patients,  
471 hypertension was identified as a major independent predictor of early-EPC blunted  
472 migratory capacity (33). Also, compared with healthy individuals, in prehypertension  
473 and hypertension subjects *in vivo* endothelial repair capacity by early-EPC is  
474 considerable reduced, and this is related to accelerated early-EPC senescence and  
475 impaired endothelial function. Of note, early-EPC telomere length is negatively related  
476 to systolic blood pressure (16). In addition, both in the rat and in humans, hypertension  
477 is associated with increased numbers of senescent circulating EPC (38). EPC  
478 mobilization from the bone marrow is dependent on NO-mediated activation of MMP-9.

479 Recent experimental evidence supports the concept that in hypertension the  
480 impairment of EPC mobilization results from insufficient bone marrow NO synthase  
481 activity, and the consequent deficiency in NO/MMP-9 signaling (3). Interestingly, in  
482 experimental renovascular hypertension improvements of *in vivo* repair capacity, *in*  
483 *vitro* EPC proliferation, and tube formation and homing signals (VEGF and homing  
484 receptor expression) are present in the early phase of the disease; however, this  
485 putative early compensatory vascular response is lost with longer lasting hypertension  
486 (39). In the present paper, we report additional factors that can interfere with adequate  
487 EPC function in hypertension.

488 Our findings may help to explain why hypertensive patients that have achieved target  
489 blood pressure levels through pharmacological treatment still display a high residual  
490 cardiovascular risk. Of note, a recent review (30) emphasized the concept that  
491 sympathetic nervous system activation is frequently responsible for the origin and  
492 maintenance of elevated blood pressure in essential hypertension, and that at present  
493 sympathetic antagonists are underused as treatments for hypertensive patients. If

494 further studies replicate these findings, the next step would be to test whether by  
495 antagonizing the sympathetic nervous system it is possible to increase EPC numbers  
496 in association with the improvement of endothelial function.

497

498 **Grants**

499 This work was supported by a grant from Agencia Nacional de Promoción Científica y  
500 Tecnológica (ANPCyT)-Argentina and the School of Biomedical Science, Austral  
501 University [PICTO Austral 2008-00051 to E.M.V.C.]. The funding agency had no role  
502 in the conception, execution, or analysis of the research and drafting of the article.

503

504

505 **Conflict of Interest**

506 None declared

507

508 **References**

- 509 1. Heart rate variability: standards of measurement, physiological interpretation and  
510 clinical use. Task Force of the European Society of Cardiology and the North American Society  
511 of Pacing and Electrophysiology. *Circulation* 93: 1043-1065, 1996.
- 512 2. **Abounit S and Zurzolo C.** Wiring through tunneling nanotubes--from electrical signals  
513 to organelle transfer. *J Cell Sci* 125: 1089-1098, 2012.
- 514 3. **Aleksinskaya MA, van Faassen EE, Nelissen J, Janssen BJ, De Mey JG, Hanemaaijer R,  
515 Rabelink T, and van Zonneveld AJ.** Identification of free nitric oxide radicals in rat bone  
516 marrow: implications for progenitor cell mobilization in hypertension. *PLoS One* 8: e57761,  
517 2013.
- 518 4. **Alkondon M, Pereira EF, Cortes WS, Maelicke A, and Albuquerque EX.** Choline is a  
519 selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. *Eur J*  
520 *Neurosci* 9: 2734-2742, 1997.
- 521 5. **Bajayo A, Bar A, Denes A, Bachar M, Kram V, Attar-Namdar M, Zallone A, Kovacs KJ,  
522 Yirmiya R, and Bab I.** Skeletal parasympathetic innervation communicates central IL-1 signals  
523 regulating bone mass accrual. *Proc Natl Acad Sci U S A* 109: 15455-15460, 2012.
- 524 6. **Cooke JP and Ghebremariam YT.** Endothelial nicotinic acetylcholine receptors and  
525 angiogenesis. *Trends Cardiovasc Med* 18: 247-253, 2008.
- 526 7. **Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA,  
527 Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, and Vogel R.**  
528 Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated  
529 vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task  
530 Force. *J Am Coll Cardiol* 39: 257-265, 2002.
- 531 8. **Chen H, Yiu KH, and Tse HF.** Relationships between vascular dysfunction, circulating  
532 endothelial progenitor cells, and psychological status in healthy subjects. *Depress Anxiety* 28:  
533 719-727, 2011.
- 534 9. **Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW,  
535 Materson BJ, Oparil S, Wright JT, Jr., and Roccella EJ.** Seventh report of the Joint National  
536 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  
537 *Hypertension* 42: 1206-1252, 2003.
- 538 10. **DiBona GF and Esler M.** Translational medicine: the antihypertensive effect of renal  
539 denervation. *Am J Physiol Regul Integr Comp Physiol* 298: R245-253, 2010.
- 540 11. **Dodt C, Breckling U, Derad I, Fehm HL, and Born J.** Plasma epinephrine and  
541 norepinephrine concentrations of healthy humans associated with nighttime sleep and  
542 morning arousal. *Hypertension* 30: 71-76, 1997.
- 543 12. **Elenkov IJ, Wilder RL, Chrousos GP, and Vizi ES.** The sympathetic nerve--an integrative  
544 interface between two supersystems: the brain and the immune system. *Pharmacol Rev* 52:  
545 595-638, 2000.
- 546 13. **Fischer JC, Kudielka BM, von Kanel R, Siegrist J, Thayer JF, and Fischer JE.** Bone-  
547 marrow derived progenitor cells are associated with psychosocial determinants of health after  
548 controlling for classical biological and behavioral cardiovascular risk factors. *Brain Behav*  
549 *Immun* 23: 419-426, 2009.
- 550 14. **Galasso G, De Rosa R, Ciccarelli M, Sorriento D, Del Giudice C, Strisciuglio T, De Biase  
551 C, Luciano R, Piccolo R, Pierri A, Di Gioia G, Prevete N, Trimarco B, Piscione F, and Iaccarino  
552 G.** beta2-Adrenergic receptor stimulation improves endothelial progenitor cell-mediated  
553 ischemic neoangiogenesis. *Circ Res* 112: 1026-1034, 2013.
- 554 15. **George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A, Mittelman A,  
555 and Tiwari RK.** Endothelial progenitor cell biology in disease and tissue regeneration. *J*  
556 *Hematol Oncol* 4: 24, 2011.

- 557 16. **Giannotti G, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horvath T, Jiang H,**  
558 **Sorrentino SA, Steenken N, Manes C, Marzilli M, Rudolph KL, Luscher TF, Drexler H, and**  
559 **Landmesser U.** Impaired endothelial repair capacity of early endothelial progenitor cells in  
560 prehypertension: relation to endothelial dysfunction. *Hypertension* 55: 1389-1397, 2010.
- 561 17. **Goldstein DS.** Plasma norepinephrine during stress in essential hypertension.  
562 *Hypertension* 3: 551-556, 1981.
- 563 18. **Heeschen C, Chang E, Aicher A, and Cooke JP.** Endothelial progenitor cells participate  
564 in nicotine-mediated angiogenesis. *J Am Coll Cardiol* 48: 2553-2560, 2006.
- 565 19. **Heeschen C, Weis M, Aicher A, Dimmeler S, and Cooke JP.** A novel angiogenic  
566 pathway mediated by non-neuronal nicotinic acetylcholine receptors. *J Clin Invest* 110: 527-  
567 536, 2002.
- 568 20. **Hirschi KK, Ingram DA, and Yoder MC.** Assessing identity, phenotype, and fate of  
569 endothelial progenitor cells. *Arterioscler Thromb Vasc Biol* 28: 1584-1595, 2008.
- 570 21. **Imanishi T, Moriwaki C, Hano T, and Nishio I.** Endothelial progenitor cell senescence is  
571 accelerated in both experimental hypertensive rats and patients with essential hypertension. *J*  
572 *Hypertens* 23: 1831-1837, 2005.
- 573 22. **Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, and Frenette PS.**  
574 Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from  
575 bone marrow. *Cell* 124: 407-421, 2006.
- 576 23. **Kirkpatrick CJ, Bittinger F, Nozadze K, and Wessler I.** Expression and function of the  
577 non-neuronal cholinergic system in endothelial cells. *Life Sci* 72: 2111-2116, 2003.
- 578 24. **Liu X, Tan W, Liu Y, Lin G, and Xie C.** The role of the beta2 adrenergic receptor on  
579 endothelial progenitor cells dysfunction of proliferation and migration in chronic obstructive  
580 pulmonary disease patients. *Expert Opin Ther Targets* 17: 485-500, 2013.
- 581 25. **Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E,**  
582 **Mancina R, Netti GS, Becherucci F, Gacci M, Carini M, Gesualdo L, Rotondi M, Maggi E,**  
583 **Lasagni L, Serio M, Romagnani S, and Romagnani P.** Essential but differential role for CXCR4  
584 and CXCR7 in the therapeutic homing of human renal progenitor cells. *J Exp Med* 205: 479-490,  
585 2008.
- 586 26. **Medina RJ, O'Neill CL, O'Doherty TM, Knott H, Guduric-Fuchs J, Gardiner TA, and Stitt**  
587 **AW.** Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis  
588 through interleukin-8. *Mol Med* 17: 1045-1055, 2011.
- 589 27. **Medina RJ, O'Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, and**  
590 **Stitt AW.** Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct  
591 cell populations with different identities. *BMC Med Genomics* 3: 18, 2010.
- 592 28. **Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, and Rafii S.** Mobilization  
593 of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated  
594 elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. *Ann N Y Acad Sci* 938: 36-45;  
595 discussion 45-37, 2001.
- 596 29. **Nunan D, Sandercock GR, and Brodie DA.** A quantitative systematic review of normal  
597 values for short-term heart rate variability in healthy adults. *Pacing Clin Electrophysiol* 33:  
598 1407-1417, 2010.
- 599 30. **Parati G and Esler M.** The human sympathetic nervous system: its relevance in  
600 hypertension and heart failure. *Eur Heart J* 33: 1058-1066, 2012.
- 601 31. **Recalde A, Richart A, Guerin C, Cochain C, Zouggar Y, Yin KH, Vilar J, Drouet I, Levy B,**  
602 **Varoquaux O, and Silvestre JS.** Sympathetic nervous system regulates bone marrow-derived  
603 cell egress through endothelial nitric oxide synthase activation: role in postischemic tissue  
604 remodeling. *Arterioscler Thromb Vasc Biol* 32: 643-653, 2012.
- 605 32. **Steinmetz M, Pelster B, Lucanus E, Arnal JF, Nickenig G, and Werner N.** Atorvastatin-  
606 induced increase in progenitor cell levels is rather caused by enhanced receptor activator of  
607 NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization. *J Mol Cell*  
608 *Cardiol* 57: 32-42, 2013.

- 609 33. **Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, and**  
610 **Dimmeler S.** Number and migratory activity of circulating endothelial progenitor cells inversely  
611 correlate with risk factors for coronary artery disease. *Circ Res* 89: E1-7, 2001.
- 612 34. **Yasuda K, Khandare A, Burianovskyy L, Maruyama S, Zhang F, Nasjletti A, and**  
613 **Goligorsky MS.** Tunneling nanotubes mediate rescue of prematurely senescent endothelial  
614 cells by endothelial progenitors: exchange of lysosomal pool. *Aging (Albany NY)* 3: 597-608,  
615 2011.
- 616 35. **Yasuda K, Park HC, Ratliff B, Addabbo F, Hatzopoulos AK, Chander P, and Goligorsky**  
617 **MS.** Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair. *Am J*  
618 *Pathol* 176: 1685-1695, 2010.
- 619 36. **Yu M, Liu Q, Sun J, Yi K, Wu L, and Tan X.** Nicotine improves the functional activity of  
620 late endothelial progenitor cells via nicotinic acetylcholine receptors. *Biochem Cell Biol* 89:  
621 405-410, 2011.
- 622 37. **Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M, and Giacca M.** Bone  
623 marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but  
624 are not incorporated into the newly formed vessels. *Blood* 107: 3546-3554, 2006.
- 625 38. **Zhou Z, Peng J, Wang CJ, Li D, Li TT, Hu CP, Chen XP, and Li YJ.** Accelerated senescence  
626 of endothelial progenitor cells in hypertension is related to the reduction of calcitonin gene-  
627 related peptide. *J Hypertens* 28: 931-939, 2010.
- 628 39. **Zhu XY, Urbieta Caceres VH, Favreau FD, Krier JD, Lerman A, and Lerman LO.**  
629 Enhanced endothelial progenitor cell angiogenic potency, present in early experimental  
630 renovascular hypertension, deteriorates with disease duration. *J Hypertens* 29: 1972-1979,  
631 2011.
- 632
- 633
- 634
- 635

636 **FIGURE TITLES**

637 **FIGURE 1. Immunohistochemical characterization of cultured human early- and**  
638 **late-EPC**

639

640 **FIGURE 2. Characterization of tunneling nanotubes in cultured human early- and**  
641 **late-EPC**

642

643 **FIGURE 3. Relation between autonomic status and EPC or TNT numbers in**  
644 **treated hypertensive patients after natural log transformation of variables**  
645 **followed by linear regression analysis**

646

647 **FIGURE 4. Effects of epinephrine and norepinephrine on cultured EPC adhesion**  
648 **and growth.**

649

650 **FIGURE 5. Relation between flow-dependent, endothelium-mediated dilation and**  
651 **early-EPC numbers in treated hypertensive patients after natural log**  
652 **transformation of variables followed by linear regression analysis**

653

654 **TABLE TITLES**

655 **TABLE 1. Subjects' characteristics**

656 **TABLE 2. Quantification of cultured early-EPC, early-TNT, late-EPC and late-TNT**  
657 **isolated from peripheral blood in treated essential hypertensive patients and**  
658 **normotensive subjects**

659

660 **TABLE 3. Cardiac parasympathetic reserve and sympathetic response, and the**  
661 **relation between autonomic status and EPC or TNT numbers in treated essential**  
662 **hypertensive patients**

663

664

665

666

667

668

669

670 **FIGURE LEGENDS**

671 **Figure 1.** Endothelial progenitor cells were obtained after culturing peripheral blood  
672 mononuclear cells on either human fibronectin or rat collagen for early- and late-EPC,  
673 respectively. The cells were characterized by immunocytochemistry on days 9 (early-  
674 EPC) and 21 (late-EPC) of culture. A. Early-EPC –but not late-EPC- expressed the  
675 haematopoietic markers CD14 and CD45, indicating that late-EPC are committed to  
676 the endothelial lineage. B. Merged fluorescence images show that early-EPC were  
677 positive for both CD14 and CD45 and all CD14+ cells were also positive for Dil-  
678 acetylated LDL, indicating that the cells were not a mixture of live and dead cells. Also,  
679 early-EPC were positive for both VEGFR-2 and CD45.

680  
681 **Figure 2.** Tunneling nanotubes (TNT) were identified as thin, straight, actin-rich  
682 (Phalloidin staining) cytoplasmic projections, with a length equivalent to several cell  
683 diameters, and crossing from one cell to another. A. TNT in live early- and late-EPC; B.  
684 TNT in fixed late-EPC

685  
686 **Figure 3.** In controlled-hypertensive patients, the cardiac parasympathetic reserve was  
687 evaluated by analyzing the high frequency (HF) component of HRV during the E/I  
688 maneuver, and the cardiac sympathetic response was assessed by analyzing the  
689 LF/HF ratio during the Stroop color-word test. In this study group, late-EPC number  
690 was positively associated with cardiac parasympathetic reserve during the E/I  
691 maneuver and inversely related to cardiac sympathetic response during the stress test.

692  
693 **Figure 4. A.** To examine the effects of catecholamines on (A1) early-EPC and (A2)  
694 late-EPC adhesion to fibronectin or collagen, respectively, epinephrine or  
695 norepinephrine were added to the culture medium at the time of seeding onto culture  
696 dishes, and adherent EPC were counted 48 h later. Data are presented as median  
697 (minimum-maximal values) of 6 independent assays. Epi = epinephrine; Norepi =  
698 norepinephrine; \* P = 0.0235 vs. PBS; † P = 0.0314 vs. 100 ng epinephrine/L; ‡ P =  
699 0.0399 vs. PBS ; § P = 0.030 vs. 100 ng norepinephrine/L; ¶ P = 0.0399 vs. PBS **B.**  
700 To investigate the effects of catecholamines on (B1) early- and (B2) late-EPC growth,  
701 epinephrine or norepinephrine were added to the culture medium 48 h after seeding  
702 and cells were counted on days 9 or 21, respectively. \* 0.0314 vs. PBS; † P = 0.0399  
703 vs. 100 ng epinephrine/L; ‡ 0.025 vs. PBS; ¶ P = 0.0399 vs. PBS.

704  
705 **Figure 5.** In controlled-hypertensive patients, *ex vivo* cultured early-EPC counts were  
706 positively correlated with flow-dependent, endothelium-mediated dilation (FMD).  
707

708

709

710

711

712

713 **TABLE LEGENDS**

714 **TABLE 1.** Values are expressed as median (max - min value).

715 **TABLE 2. A.** Shows the numbers of cultured early- (day 9) and late-EPC (day 21) per  
716 microscopic field that were isolated from peripheral blood in controlled essential  
717 hypertensive patients (Hypertensive) and normotensive individuals (Normotensive) and  
718 seeded onto fibronectin (early-EPC) or collagen (late-EPC). **B.** Shows the percentage  
719 of cultured early-EPC (day 9) and late-EPC (day 21) that emitted TNT in cells isolated  
720 from treated essential hypertensive patients and normotensive subjects. Values are  
721 expressed as median (max - min value). early-TNT= number of early-EPC that project  
722 tunneling nanotubes; late-TNT= number of late-EPC that project tunneling nanotubes.  
723 Values are expressed as median (max - min value). early-TNT= number of early-EPC  
724 that project tunneling nanotubes; late-TNT= number of late-EPC that project tunneling  
725 nanotubes.

726 **TABLE 3.** In hypertensive patients (N=30), autonomic status was assessed by  
727 frequency domain analysis of short-term heart rate variability (HRV). **A.** Low-(LF) and  
728 high-frequency (HF) components of short-term heart rate variability (HRV) were  
729 analyzed during a 5-min rest, an expiration/inspiration maneuver, and a Stroop color-  
730 word-test. Values are expressed as median (max - min value). **B.** In hypertensive  
731 patients, late-EPC number was positively related to the cardiac parasympathetic  
732 reserve during the E/I maneuver, and late-TNT numbers were negatively associated  
733 with sympathetic response during the mental stress test. \*Increase in HF component of  
734 heart rate variability during the E/I maneuver, †Low/high frequency ratio (LF/HF) during  
735 the mental stress test.

736


737

738


739

**A**


**Early-EPC (Immunofluorescence, day 9)**



**Late-EPC (Immunofluorescence, day 21)**




**B**



**A**


**TNT in Early-EPC**



*Optical Microscopy 400x; Zoom 3x*

*F-Actin Staining (Phalloidin)*


**TNT in Late-EPC**



*Optical Microscopy 400x; Zoom 3x*

**B**


**TNT in Late-EPC**



*Optical Microscopy 400x; Zoom 3x*


**A**


Cardiac parasympathetic reserve during the E/I test vs. Late-EPC number




**B**

Cardiac sympathetic response during the stress test vs. Late-TNT number







**A1. Early-EPC adhesion to fibronectin**




**A2. Late-EPC adhesion to collagen**



**B1. Early-EPC proliferation on fibronectin**



**B2. Late-EPC proliferation on collagen**



**TABLE 1. Subjects' characteristics**

<b>Characteristic</b>	<b>Hypertensive (N=30)</b>	<b>Normotensive (N=20)</b>	<b>P value</b>
Age, y	49 (24-69)	50 (27-66)	0.780
Males, %	81.8	80.0	-----
SBP, mm Hg	130 (120-137)	114 (107-119)	0.008
DBP, mmHg	85 (61-88)	75 (64-79)	0.039
Medications, %		None	-----
ACEI/ARAI	63.5		
Ca <sup>2+</sup> Antagonist	33		
Diuretics	13		
Statins	17		
Other	18		
BMI, kg/m <sup>2</sup>	28.0 (19.1-39.0)	25.0 (18.1-27.8)	0.1189
Total cholesterol, mmol/L	4.96 (3.93-6.44)	3.99 (3.41-5.17)	0.0518
HDL cholesterol, mmol/L	1.34 (1.06-2.33)	1.86 (1.19-2.64)	0.1564
LDL cholesterol, mmol/L	3.06(1.81-4.19)	2.60 (2.12-3.15)	0.2120
TG, mmol/L	1.05 (0.54-2.10)	0.85 (0.74-1.24)	0.0272
Glycemia, mmol/L	5.05 (4.50-6.22)	4.91 (4.78-5.22)	0.4715

Values are expressed as median (max - min value).

**TABLE 2.****A.**

<b>Type of EPC or TNT (No./microscopic field)</b>	<b>Hypertensive (N=30)</b>	<b>Normotensive (N=20)</b>	<b>P Value</b>
early-EPC	223.5 (87.8 - 551)	392 (248 - 681)	0.0015
early-TNT	13.2 (0.83 - 54.5)	59.7 (24.8 - 99.8)	0.0002
late-EPC	157.6 (52.4 - 409)	324 (215 - 634)	0.005
late-TNT	2.60 (0 - 29.3)	24.2 (19.2 - 44.6)	0.008

**B.**

	<b>Hypertensive (N =30)</b>	<b>Normotensive (N=20)</b>	<b>P Value</b>
(early-TNT/early-EPC) x 100, %	5.30 (0 – 17.6)	12.3 (5.89-28.2)	0.012
(late-TNT/late-EPC) x 100, %	2.30 (0 – 13.1)	7.51 (3.0 – 15.6)	0.017

**TABLE 3.****A.**

Settings at the time of measurement	Parameter	
	HF, ms <sup>2</sup>	LF/HF, %
During a 5-min rest	177 (22 - 934)	2.15 (0.40 - 10.5)
During an E/I maneuver	431 (37 - 2791)	10.3 (1.30 - 50)
During a mental stress test	120 (6 - 570)	4.10 (0.40 - 14.1)

**B.**

Parameters related	Correlation (Spearman rho)	P Value
Late-EPC number and cardiac parasympathetic reserve*	0.450	0.031
Late-TNT and cardiac sympathetic response <sup>†</sup>	-0.426	0.045